Selected article for: "logistic regression and longitudinal observational"

Author: Clemente, D.; Udaondo, C.; de Inocencio, J.; Nieto, J. C.; Galan del Rio, P.; Garcia Fernandez, A.; Arroyo Palomo, J.; Bachiller-Corral, J.; Lopez Robledillo, J. C.; Leon, L.; Abasolo, L.; Boteanu, A.
Title: Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases
  • Cord-id: sqtz3pto
  • Document date: 2021_5_20
  • ID: sqtz3pto
    Snippet: Background: This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death. Methods: An observational longitudinal study was conducted during the first year of pandemic SARS-CoV-2 (1st March 2020 to 1st March 2021). All pediatric pat
    Document: Background: This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death. Methods: An observational longitudinal study was conducted during the first year of pandemic SARS-CoV-2 (1st March 2020 to 1st March 2021). All pediatric patients attended at the rheumatology outpatient clinic of six tertiary hospital in Madrid, Spain, with a medical diagnosis of RMD and COVID-19 were included. Main outcomes were symptomatic disease and hospital admission. The covariates were sociodemographic, clinical, and treatments. We ran a multivariable logistic regression model to assess risk factors for outcomes. Results: The study population included 77 pediatric patients. Mean age was 11.88 (4.04) years Of these, 30 patients were asymptomatic, 41 had a mild or moderate disease and other 6 patients (7.79%) required hospital admission related to COVID-19. The median length of stay was 5 (2-20) days and there was no death. Previous comorbidities increased the risk for symptomatic disease and hospital admission. Compared with outpatients, the factor independently associated with hospital admission was the use of glucocorticoids (OR 1.08; p=0.00). No statistically significant findings for symptomatic COVID-19 were found in the final model. Conclusion: Our data found no differences in COVID-19 outcomes between children-onset rheumatic diseases. Our results suggest that associated comorbidities and being in treatment with glucocorticoids increase the risk of hospital admission.

    Search related documents:
    Co phrase search for related documents
    • logistic regression analysis and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • logistic regression analysis and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
    • logistic regression analysis and macrophage activation: 1, 2, 3
    • logistic regression analysis and macrophage activation syndrome: 1, 2, 3
    • logistic regression analysis and madrid community: 1
    • logistic regression analysis and madrid region: 1
    • logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
    • logistic regression and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • logistic regression and macrophage activation: 1, 2, 3, 4
    • logistic regression and macrophage activation syndrome: 1, 2, 3, 4
    • logistic regression and madrid community: 1, 2
    • logistic regression and madrid region: 1, 2
    • logistic regression model and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • logistic regression model and lupus erythematosus: 1, 2, 3
    • lopinavir ritonavir and lupus erythematosus: 1, 2, 3, 4
    • lopinavir ritonavir and macrophage activation: 1, 2, 3
    • lopinavir ritonavir and macrophage activation syndrome: 1, 2, 3
    • lupus erythematosus and macrophage activation: 1, 2, 3, 4, 5
    • lupus erythematosus and macrophage activation syndrome: 1, 2, 3, 4